Follow
Max Kates
Max Kates
Associate Professor, Johns Hopkins Hospital
Verified email at jhmi.edu - Homepage
Title
Cited by
Cited by
Year
Survival following lobectomy and limited resection for the treatment of stage I non-small cell lung cancer≤ 1 cm in size: a review of SEER data
M Kates, S Swanson, JP Wisnivesky
Chest 139 (3), 491-496, 2011
2312011
Post-percutaneous nephrolithotomy systemic inflammatory response: a prospective analysis of preoperative urine, renal pelvic urine and stone cultures
R Korets, JA Graversen, M Kates, AC Mues, M Gupta
The Journal of urology 186 (5), 1899-1903, 2011
2132011
Cause of death and predictors of all‐cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF
SD Pokorney, JP Piccini, SR Stevens, MR Patel, KS Pieper, JL Halperin, ...
Journal of the American Heart Association 5 (3), e002197, 2016
1522016
The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial …
AS Baras, C Drake, JJ Liu, N Gandhi, M Kates, MO Hoque, A Meeker, ...
Oncoimmunology 5 (5), e1134412, 2016
1462016
Survival after partial and radical nephrectomy for the treatment of stage T1bN0M0 renal cell carcinoma (RCC) in the USA: a propensity scoring approach
GM Badalato, M Kates, JP Wisnivesky, AR Choudhury, JM McKiernan
BJU international 109 (10), 1457-1462, 2012
1362012
Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer
RL Steinberg, LJ Thomas, N Brooks, SL Mott, A Vitale, T Crump, MY Rao, ...
The Journal of urology 203 (5), 902-909, 2020
1262020
Frailty as a marker of adverse outcomes in patients with bladder cancer undergoing radical cystectomy
MR Chappidi, M Kates, HD Patel, JJ Tosoian, DR Kaye, NA Sopko, ...
Urologic oncology: seminars and original investigations 34 (6), 256. e1-256. e6, 2016
1212016
Adaptive immune resistance to intravesical BCG in non–muscle invasive bladder cancer: Implications for prospective BCG-unresponsive trials
M Kates, A Matoso, W Choi, AS Baras, MJ Daniels, K Lombardo, A Brant, ...
Clinical cancer research 26 (4), 882-891, 2020
1152020
Validation of a frailty index in patients undergoing curative surgery for urologic malignancy and comparison with other risk stratification tools
D Lascano, JS Pak, M Kates, JB Finkelstein, M Silva, E Hagen, ...
Urologic Oncology: Seminars and Original Investigations 33 (10), 426. e1-426 …, 2015
1102015
Morbidity of urologic surgical procedures: an analysis of rates, risk factors, and outcomes
HD Patel, MW Ball, JE Cohen, M Kates, PM Pierorazio, ME Allaf
Urology 85 (3), 552-560, 2015
1032015
Increased risk of overall and cardiovascular mortality after radical nephrectomy for renal cell carcinoma 2 cm or less
M Kates, GM Badalato, M Pitman, JM McKiernan
The Journal of urology 186 (4), 1247-1253, 2011
952011
Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Guérin …
JM McKiernan, DD Holder, RA Ghandour, LMJ Barlow, JJ Ahn, M Kates, ...
The Journal of urology 192 (6), 1633-1638, 2014
872014
Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis
C Tsao, AC Small, M Kates, EL Moshier, JP Wisnivesky, BA Gartrell, ...
World journal of urology 31, 1535-1539, 2013
792013
Hospital charges and length of stay following radical cystectomy in the enhanced recovery after surgery era
A Semerjian, N Milbar, M Kates, MA Gorin, HD Patel, HJ Chalfin, ...
Urology 111, 86-91, 2018
762018
Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer
N Milbar, M Kates, MR Chappidi, F Pederzoli, T Yoshida, A Sankin, ...
Bladder Cancer 3 (4), 293-303, 2017
762017
Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer
M Kates, T Nirschl, NA Sopko, H Matsui, CM Kochel, LO Reis, GJ Netto, ...
Cancer immunology research 5 (7), 594-603, 2017
702017
Expression of nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes
JH Hoffman-Censits, KA Lombardo, V Parimi, S Kamanda, W Choi, ...
Applied Immunohistochemistry & Molecular Morphology 29 (8), 619-625, 2021
642021
Predictive biomarkers for drug response in bladder cancer
T Yoshida, M Kates, K Fujita, TJ Bivalacqua, DJ McConkey
International Journal of Urology 26 (11), 1044-1053, 2019
612019
Three-dimensional organoid culture reveals involvement of Wnt/β-catenin pathway in proliferation of bladder cancer cells
T Yoshida, NA Sopko, M Kates, X Liu, G Joice, DJ McConkey, ...
Oncotarget 9 (13), 11060, 2018
572018
Importance of reporting the Gleason score at the positive surgical margin site: analysis of 4,082 consecutive radical prostatectomy cases
M Kates, NA Sopko, M Han, AW Partin, JI Epstein
The Journal of urology 195 (2), 337-342, 2016
562016
The system can't perform the operation now. Try again later.
Articles 1–20